Today, Zacks Investment Ideas feature highlights Gilead Sciences GILD and Johnson & Johnson JNJ. Buy Gilead Sciences (GILD ...

Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Gilead Sciences's GILD short percent of float has risen 6.47% since its last report. The company recently reported that it ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

NORTHAMPTON, MA / ACCESS Newswire / March 14, 2025 / In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...